Chemomab Therapeutics Ltd. (CMMB) is a publicly traded company in the Unknown sector. Across all available filings, 9 corporate insiders have executed 29 transactions totaling $2.7M, demonstrating a bearish sentiment with -$2.3M in net insider flow. The most recent transaction on Jan 3, 2023 involved a sale of 7,700 shares valued at $38.7K.
No significant insider buying has been recorded for CMMB in the recent period.
No significant insider selling has been recorded for CMMB in the recent period.
Based on recent SEC filings, insider sentiment for CMMB is bearish with an Insider Alignment Score of 7/100 and a net flow of -$2.3M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Chemomab Therapeutics Ltd. (CMMB) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 9 insiders are actively trading CMMB stock, having executed 29 transactions in the past 90 days. The most active insider is Israel Gp Ltd. Orbimed (Executive), who has made 1 transactions totaling $5.0M.
Get notified when executives and directors at CMMB file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | Adi Mor George | Executive | Sale | 7,700 | $5.03 | $38.7K | |
| Jan 3, 2023 | Adi Mor George | Executive | Sale | 6,100 | $5.03 | $30.7K | |
| Jan 3, 2023 | Biofund Gp Limited Partnership Orbimed Israel | Executive | Sale | 266,376 | $3.34 | $889.7K | Large |
| Jan 3, 2023 | Biofund Gp Limited Partnership Orbimed Israel | Executive | Sale | 70,524 | $4.51 | $318.1K | |
| Nov 16, 2022 | Adi Mor George | Executive | Sale | 257,248 | $2.08 | $535.1K | Large |
| Nov 16, 2022 | Adi Mor George | Executive | Sale | 324,775 | $2.08 | $675.5K | Large |
| Nov 16, 2022 | Harris Cohen Neil | Executive | Sale | 2,409 | $2.00 | $4.8K | |
| May 24, 2022 | Michael Maryles Joel | Executive | Purchase | 33 | $2.76 | $91 | |
| May 24, 2022 | Michael Maryles Joel | Executive | Purchase | 400 | $2.89 | $1.2K | |
| May 18, 2022 | Harris Cohen Neil | Executive | Purchase | 2,000 | $3.19 | $6.4K | |
| Mar 18, 2022 | Michael Maryles Joel | Executive | Purchase | 500 | $4.32 | $2.2K | |
| Mar 18, 2022 | Michael Maryles Joel | Executive | Purchase | 500 | $4.36 | $2.2K | |
| Mar 16, 2022 | Marvin Donald | Executive | Purchase | 250 | $3.25 | $813 | |
| Mar 16, 2022 | Marvin Donald | Executive | Purchase | 250 | $3.30 | $825 | |
| Mar 14, 2022 | Harris Cohen Neil | Executive | Purchase | 2,000 | $4.20 | $8.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Award(A) | 1 | $5.0M | 65.2% |
Sale(S) | 7 | $2.5M | 32.5% |
Purchase(P) | 21 | $174.7K | 2.3% |
Insider selling pressure at Chemomab Therapeutics Ltd. has increased, with 9 insiders executing 29 transactions across all time. Total sales of $2.5M significantly outpace purchases of $174.7K, resulting in a net outflow of $2.3M. This selling activity appears largely discretionary, which may warrant closer attention from investors.